Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 57.59 -0.06 (-0.10%) Streaming Delayed Price Updated: 2:52 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 ... 30 31 Next > Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts April 08, 2024 Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward. Via InvestorPlace Topics Workforce Exposures Layoff In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster April 04, 2024 Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. Via Benzinga Topics Lawsuit Exposures Financial Legal What's Going On European Pharma Giant AstraZeneca Stock On Wednesday? March 27, 2024 Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... Via Benzinga How Is The Market Feeling About Sanofi? March 27, 2024 Via Benzinga Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath' March 26, 2024 Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. Via Benzinga (SNY) - Analyzing Sanofi's Short Interest March 08, 2024 Via Benzinga Why the dividend investor may take a look at NASDAQ:SNY. February 14, 2024 Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. Via Chartmill NASDAQ:SNY is an undervalued gem with solid fundamentals. February 14, 2024 SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill To the Moon and Beyond: 7 Stocks With Cosmic Potential March 14, 2024 With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. Via InvestorPlace Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings March 13, 2024 With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities. Via InvestorPlace Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits March 04, 2024 Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. Via InvestorPlace 11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields February 28, 2024 A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. Via Benzinga 3 Cash Cow Dividend Stocks for Outsized Income & Upside February 27, 2024 With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks. Via InvestorPlace 6 reasons to buy Teva Pharmaceuticals stock sooner than later February 26, 2024 Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why Via MarketBeat Topics Lawsuit Exposures Financial Legal Move Over Magnificent 7, Say Hello to the GRANOLAS February 22, 2024 Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. Via InvestorPlace Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests February 20, 2024 The FDA put studies in eczema and asthma treatment on clinical hold. Via Investor's Business Daily Exposures Product Safety Cruising For A Bruising February 18, 2024 We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... Via Talk Markets Topics Economy Exposures Economy Interest Rates 2 Healthcare Stocks You Can Buy and Hold for the Next Decade February 16, 2024 Don't count these companies out too soon. Via The Motley Fool 7 Contrarian Biotech Stocks to Consider Amid Sector Weakness February 15, 2024 Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. Via InvestorPlace The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. Via InvestorPlace What's Going On Eli Lilly Stock Thursday? February 08, 2024 Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. Via Benzinga Novo Nordisk To Up Production Capacity As Parent Buys Catalent February 05, 2024 NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. Via Investor's Business Daily CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development February 05, 2024 Click here to learn more about CytoReason and how to invest through OurCrowd. Via Benzinga Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets February 03, 2024 Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. Via Talk Markets Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? February 02, 2024 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. Via Benzinga Sanofi (SNY) Q4 2023 Earnings Call Transcript February 01, 2024 SNY earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session February 01, 2024 Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. Via Benzinga French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs February 01, 2024 Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge. Via Benzinga Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. February 01, 2024 The company missed total sales and earnings expectations. Via Investor's Business Daily Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year February 01, 2024 After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 30 31 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.